Skip to main content
Book cover

Ghrelin in Health and Disease pp 91–110Cite as

Ghrelin Regulation of AMPK in the Hypothalamus and Peripheral Tissues

Part of the Contemporary Endocrinology book series (COE,volume 10)

Abstract

Adenosine 5′ monophosphate-activated protein kinase (AMPK) is a regulator of cellular and systemic energy homeostasis. Several appetite-regulating and metabolic hormones are known to influence AMPK. Ghrelin displays central orexigenic as well as direct peripheral metabolic effects and both could be related to its effects on AMPK activity. In the hypothalamus ghrelin stimulates AMPK and this has been associated with its orexigenic effects. Evidence suggests a tight interaction between the central ghrelin and cannabinoid systems, and hypothalamic AMPK appears to be a common mediator of their orexigenic effects. In the liver and adipose tissue, ghrelin inhibits AMPK and this could be the underlying mechanism for its diabetogenic and lipogenic effects. While in cardiac muscle, ghrelin stimulates AMPK which could be linked to its positive inotropic effects. In summary, tissue-specific alterations of AMPK activity play an important role in the diverse effects of ghrelin.

Keywords

  • Fatty Acid Amide Hydrolase
  • CPT1 Activity
  • Orexigenic Effect
  • Ghrelin Treatment
  • Central Ghrelin

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-61779-903-7_5
  • Chapter length: 20 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   129.00
Price excludes VAT (USA)
  • ISBN: 978-1-61779-903-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   119.99
Price excludes VAT (USA)
Hardcover Book
USD   169.99
Price excludes VAT (USA)
Learn about institutional subscriptions
Fig. 5.1
Fig. 5.2
Fig. 5.3

References

  1. Carling D. AMPK. Curr Biol. 2004;14:R220.

    PubMed  CAS  Google Scholar 

  2. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15–25.

    PubMed  CAS  Google Scholar 

  3. Xiao B, Heath R, Saiu P, et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature. 2007;449:496–500.

    PubMed  CAS  Google Scholar 

  4. Kola B, Boscaro M, Rutter GA, Grossman AB, Korbonits M. Expanding role of AMPK in endocrinology. Trends Endocrinol Metab. 2006;17:205–15.

    PubMed  CAS  Google Scholar 

  5. Hardie DG, Sakamoto K. AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology (Bethesda). 2006;21:48–60.

    CAS  Google Scholar 

  6. Daval M, Foufelle F, Ferre P. Functions of AMP-activated protein kinase in adipose tissue. J Physiol. 2006;574:55–62.

    PubMed  CAS  Google Scholar 

  7. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol. 2010;44:87–97.

    PubMed  CAS  Google Scholar 

  8. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J. 2007; 403:139–48.

    PubMed  CAS  Google Scholar 

  9. Costanzo-Garvey DL, Pfluger PT, Dougherty MK, et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab. 2009;10:366–78.

    PubMed  CAS  Google Scholar 

  10. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 2010;1804:581–91.

    PubMed  CAS  Google Scholar 

  11. Bungard D, Fuerth BJ, Zeng PY, et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science. 2010;329:1201–5.

    PubMed  CAS  Google Scholar 

  12. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428:569–74.

    PubMed  CAS  Google Scholar 

  13. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415:339–43.

    PubMed  CAS  Google Scholar 

  14. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes. 2003;52:1355–63.

    PubMed  CAS  Google Scholar 

  15. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–95.

    PubMed  CAS  Google Scholar 

  16. Huypens P, Moens K, Heimberg H, Ling Z, Pipeleers D, Van de Casteele M. Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sci. 2005;77:1273–82.

    PubMed  CAS  Google Scholar 

  17. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia–reperfusion injury through. Nat Med. 2005;11:1096–103.

    PubMed  CAS  Google Scholar 

  18. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021–6.

    PubMed  CAS  Google Scholar 

  19. Rutter GA, Da Silva XG, Leclerc I. Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J. 2003;375:1–16.

    PubMed  CAS  Google Scholar 

  20. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem. 2003;278: 39422–7.

    PubMed  CAS  Google Scholar 

  21. Christ-Crain M, Kola B, Lolli F, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J. 2008;22: 1672–83.

    PubMed  CAS  Google Scholar 

  22. Kola B, Christ-Crain M, Lolli F, et al. Changes in adenosine 5′-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing’s syndrome. J Clin Endocrinol Metab. 2008;93:4969–73.

    PubMed  CAS  Google Scholar 

  23. Viana AY, Sakoda H, Anai M, et al. Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diabetes Res Clin Pract. 2006; 73:135–42.

    PubMed  CAS  Google Scholar 

  24. Kola B, Hubina E, Tucci SA, et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem. 2005;280: 25196–201.

    PubMed  CAS  Google Scholar 

  25. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74.

    PubMed  CAS  Google Scholar 

  26. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–6.

    PubMed  CAS  Google Scholar 

  27. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275:223–8.

    PubMed  CAS  Google Scholar 

  28. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120:2355–69.

    PubMed  CAS  Google Scholar 

  29. Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005;437:1109–11.

    PubMed  CAS  Google Scholar 

  30. He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137:635–46.

    PubMed  CAS  Google Scholar 

  31. Butler H, Korbonits M. Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol. 2009;161:655–62.

    PubMed  CAS  Google Scholar 

  32. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389–462.

    PubMed  CAS  Google Scholar 

  33. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrinol Rev. 2006;27:73–100.

    CAS  Google Scholar 

  34. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004;47 Suppl 1:345–58.

    PubMed  CAS  Google Scholar 

  35. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136:550–7.

    PubMed  CAS  Google Scholar 

  36. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822–5.

    PubMed  Google Scholar 

  37. Wittmann G, Deli L, Kallo I, et al. Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus. J Comp Neurol. 2007;503:270–9.

    PubMed  CAS  Google Scholar 

  38. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18:27–37.

    PubMed  CAS  Google Scholar 

  39. Kirkham TC, Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets. 2006;5:272–92.

    PubMed  CAS  Google Scholar 

  40. Dodd GT, Mancini G, Lutz B, Luckman SM. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. J Neurosci. 2010;30:7369–76.

    PubMed  CAS  Google Scholar 

  41. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005;8:585–9.

    PubMed  Google Scholar 

  42. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010;120:2953–66.

    PubMed  CAS  Google Scholar 

  43. Ellis J, Pediani JD, Canals M, Milasta S, Milligan G. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem. 2006;281:38812–24.

    PubMed  CAS  Google Scholar 

  44. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol. 2005;67:1697–704.

    PubMed  CAS  Google Scholar 

  45. Hojo M, Sudo Y, Ando Y, et al. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci. 2008;108:308–19.

    PubMed  CAS  Google Scholar 

  46. Schellekens H, Dinan TG, Cryan JF. Lean mean fat reducing “ghrelin” machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity. Neuropharmacology. 2010;58:2–16.

    PubMed  CAS  Google Scholar 

  47. Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol. 2004; 143:520–3.

    PubMed  CAS  Google Scholar 

  48. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85:495–522.

    PubMed  CAS  Google Scholar 

  49. Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001;50:2540–7.

    PubMed  CAS  Google Scholar 

  50. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992.

    PubMed  CAS  Google Scholar 

  51. Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology. 2003;144:544–51.

    PubMed  CAS  Google Scholar 

  52. Egecioglu E, Stenstrom B, Pinnock SB, et al. Hypothalamic gene expression following ghrelin therapy to gastrectomized rodents. Regul Pept. 2008;146:176–82.

    PubMed  CAS  Google Scholar 

  53. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003;37:649–61.

    PubMed  CAS  Google Scholar 

  54. Shuto Y, Shibasaki T, Otagiri A, et al. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest. 2002;109: 1429–36.

    PubMed  CAS  Google Scholar 

  55. Zigman JM, Nakano Y, Coppari R, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest. 2005;115:3564–72.

    PubMed  CAS  Google Scholar 

  56. Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology. 2004;145:2607–12.

    PubMed  CAS  Google Scholar 

  57. Luquet S, Perez FA, Hnasko TS, Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science. 2005;310:683–5.

    PubMed  CAS  Google Scholar 

  58. Dzamko N, van Denderen BJ, Hevener AL, et al. AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J Biol Chem. 2010;285:115–22.

    PubMed  CAS  Google Scholar 

  59. Andersson U, Filipsson K, Abbott CR, et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem. 2004;279:12005–8.

    PubMed  CAS  Google Scholar 

  60. Kohno D, Sone H, Minokoshi Y, Yada T. Ghrelin raises [Ca2+]i via AMPK in hypothalamic arcuate nucleus NPY neurons. Biochem Biophys Res Commun. 2008;366:388–92.

    PubMed  CAS  Google Scholar 

  61. Kola B, Farkas I, Christ-Crain M, et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One. 2008;3:e1797.

    PubMed  Google Scholar 

  62. Lerner RG, Depatie C, Rutter GA, Screaton RA, Balthasar N. A role for the CREB co-activator CRTC2 in the hypothalamic mechanisms linking glucose sensing with gene regulation. EMBO Rep. 2009;10:1175–81.

    PubMed  CAS  Google Scholar 

  63. Mozid AM, Tringali G, Forsling ML, et al. Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin. Horm Metab Res. 2003;35:455–9.

    PubMed  CAS  Google Scholar 

  64. Whitnall MH, Gainer H. Major pro-vasopressin-expressing and pro-vasopressin-deficient subpopulations of corticotropin-releasing hormone neurons in normal rats. Differential distributions within the paraventricular nucleus. Neuroendocrinology. 1988;47:176–80.

    PubMed  CAS  Google Scholar 

  65. Kohno D, Gao HZ, Muroya S, Kikuyama S, Yada T. Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes. 2003; 52:948–56.

    PubMed  CAS  Google Scholar 

  66. Anderson KA, Ribar TJ, Lin F, et al. Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab. 2008;7:377–88.

    PubMed  CAS  Google Scholar 

  67. Hu Z, Cha SH, Chohnan S, Lane MD. Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci U S A. 2003;100:12624–9.

    PubMed  CAS  Google Scholar 

  68. Pocai A, Lam TK, Obici S, et al. Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J Clin Invest. 2006;116:1081–91.

    PubMed  CAS  Google Scholar 

  69. Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med. 2003;9:756–61.

    PubMed  CAS  Google Scholar 

  70. Wolfgang MJ, Kurama T, Dai Y, et al. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proc Natl Acad Sci U S A. 2006;103:7282–7.

    PubMed  CAS  Google Scholar 

  71. Kola B, Korbonits M. Shedding light on the intricate puzzle of ghrelin’s effects on appetite regulation. J Endocrinol. 2009;202:191–8.

    PubMed  CAS  Google Scholar 

  72. Lopez M, Lage R, Saha AK, et al. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 2008;7:389–99.

    PubMed  CAS  Google Scholar 

  73. Andrews ZB, Liu ZW, Walllingford N, et al. UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals. Nature. 2008;454:846–51.

    PubMed  CAS  Google Scholar 

  74. Lage R, Vazquez MJ, Varela L, et al. Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. FASEB J. 2010;24:2670–9.

    PubMed  CAS  Google Scholar 

  75. Sakkou M, Wiedmer P, Anlag K, et al. A role for brain-specific homeobox factor Bsx in the control of hyperphagia and locomotory behavior. Cell Metab. 2007;5:450–63.

    PubMed  CAS  Google Scholar 

  76. Nogueiras R, Lopez M, Lage R, et al. Bsx, a novel hypothalamic factor linking feeding with locomotor activity, is regulated by energy availability. Endocrinology. 2008;149:3009–15.

    PubMed  CAS  Google Scholar 

  77. Sangiao-Alvarellos S, Varela L, Vazquez MJ, et al. Influence of ghrelin and growth hormone deficiency on AMP-activated protein kinase and hypothalamic lipid metabolism. J Neuroendocrinol. 2010;22:543–56.

    PubMed  CAS  Google Scholar 

  78. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin—a hormone with multiple functions. Front Neuroendocrinol. 2004;25:27–68.

    PubMed  CAS  Google Scholar 

  79. Toshinai K, Yamaguchi H, Sun Y, et al. Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology. 2006;147:2306–14.

    PubMed  CAS  Google Scholar 

  80. Delhanty PJ, Sun Y, Visser JA, et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS One. 2010;5:e11749.

    PubMed  Google Scholar 

  81. Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun. 2000; 279:909–13.

    PubMed  CAS  Google Scholar 

  82. Neary NM, Druce MR, Small CJ, Bloom SR. Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect. Gut. 2006;55:135.

    PubMed  CAS  Google Scholar 

  83. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87:2988.

    PubMed  CAS  Google Scholar 

  84. Iglesias MJ, Pineiro R, Blanco M, et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. 2004;62:481–8.

    PubMed  CAS  Google Scholar 

  85. Chang L, Ren Y, Liu X, et al. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol. 2004;43:165–70.

    PubMed  CAS  Google Scholar 

  86. Chang L, Zhao J, Li GZ, et al. Ghrelin protects myocardium from isoproterenol-induced injury in rats. Acta Pharmacol Sin. 2004;25:1131–7.

    PubMed  CAS  Google Scholar 

  87. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol. 2003;98:401–5.

    PubMed  CAS  Google Scholar 

  88. Korbonits M, Grossman AB. Ghrelin: update on a novel hormonal system. Eur J Endocrinol. 2004;151 Suppl 1:S67–70.

    PubMed  CAS  Google Scholar 

  89. Schwenke DO, Tokudome T, Kishimoto I, et al. Early ghrelin treatment after myocardial infarction prevents an increase in cardiac sympathetic tone and reduces mortality. Endocrinology. 2008;149:5172–6.

    PubMed  CAS  Google Scholar 

  90. Nagaya N, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. Regul Pept. 2003;114:71–7.

    PubMed  CAS  Google Scholar 

  91. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004;110:3674–9.

    PubMed  CAS  Google Scholar 

  92. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001;104:1430–5.

    PubMed  CAS  Google Scholar 

  93. Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol. 2001;280:R1483–7.

    PubMed  CAS  Google Scholar 

  94. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol. 2002; 159:1029–37.

    PubMed  CAS  Google Scholar 

  95. Jessen N, Koh HJ, Folmes CD, et al. Ablation of LKB1 in the heart leads to energy deprivation and impaired cardiac function. Biochim Biophys Acta. 2010;1802:593–600.

    PubMed  CAS  Google Scholar 

  96. Ikeda Y, Sato K, Pimentel DR, et al. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J Biol Chem. 2009;284:35839–49.

    PubMed  CAS  Google Scholar 

  97. Kusmic C, L’abbate A, Sambuceti G, et al. Improved myocardial perfusion in chronic diabetic mice by the up-regulation of pLKB1 and AMPK signaling. J Cell Biochem. 2010;109:1033–44.

    PubMed  CAS  Google Scholar 

  98. Kewalramani G, Puthanveetil P, Wang F, et al. AMP-activated protein kinase confers protection against TNF-{alpha}-induced cardiac cell death. Cardiovasc Res. 2009;84:42–53.

    PubMed  CAS  Google Scholar 

  99. Russell III RR, Li J, Coven DL, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest. 2004;114:495–503.

    PubMed  CAS  Google Scholar 

  100. Garcia EA, Korbonits M. Ghrelin and cardiovascular health. Curr Opin Pharmacol. 2006;6: 142–7.

    PubMed  CAS  Google Scholar 

  101. Xu JP, Wang HX, Wang W, Zhang LK, Tang CS. Ghrelin improves disturbed myocardial energy metabolism in rats with heart failure induced by isoproterenol. J Pept Sci. 2010;16: 392–402.

    PubMed  CAS  Google Scholar 

  102. Russell III RR, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol. 1999; 277:H643–9.

    PubMed  CAS  Google Scholar 

  103. Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol. 2000; 10:1247–55.

    PubMed  CAS  Google Scholar 

  104. Sambandam N, Lopaschuk GD. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog Lipid Res. 2003;42:238–56.

    PubMed  CAS  Google Scholar 

  105. Paiva MA, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, Mocanu MM. Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. Cardiovasc Drugs Ther. 2010;24:25–32.

    PubMed  CAS  Google Scholar 

  106. Lopaschuk GD. AMP-activated protein kinase control of energy metabolism in the ischemic heart. Int J Obes (Lond). 2008;32 Suppl 4:S29–35.

    CAS  Google Scholar 

  107. Papotti M, Ghe C, Cassoni P, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. 2000;85:3803–7.

    PubMed  CAS  Google Scholar 

  108. Murata M, Okimura Y, Lida K, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem. 2002;277:5667–74.

    PubMed  CAS  Google Scholar 

  109. Rigault C, Le BF, Georges B, Demarquoy J. Ghrelin reduces hepatic mitochondrial fatty acid beta oxidation. J Endocrinol Invest. 2007;30:RC4–8.

    PubMed  CAS  Google Scholar 

  110. Sangiao-Alvarellos S, Vazquez MJ, Varela L, et al. Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009;150:4562–74.

    PubMed  CAS  Google Scholar 

  111. Barazzoni R, Bosutti A, Stebel M, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab. 2005;288:E228–35.

    PubMed  CAS  Google Scholar 

  112. Lochhead PA, Salt IP, Walker KS, Hardie DG, Sutherland C. 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes. 2000;49:896–903.

    PubMed  CAS  Google Scholar 

  113. Assifi MM, Suchankova G, Constant S, Prentki M, Saha AK, Ruderman NB. AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Am J Physiol Endocrinol Metab. 2005;289:E794–800.

    PubMed  CAS  Google Scholar 

  114. Viollet B, Guigas B, Leclerc J, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf). 2009; 196:81–98.

    CAS  Google Scholar 

  115. Seo E, Park EJ, Joe Y, et al. Overexpression of AMPKalpha1 ameliorates fatty liver in hyperlipidemic diabetic rats. Korean J Physiol Pharmacol. 2009;13:449–54.

    PubMed  CAS  Google Scholar 

  116. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000; 407:908–13.

    PubMed  CAS  Google Scholar 

  117. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001; 280:132–8.

    PubMed  CAS  Google Scholar 

  118. Patel AD, Stanley SA, Murphy KG, et al. Ghrelin stimulates insulin-induced glucose uptake in adipocytes. Regul Pept. 2006;134:17–22.

    PubMed  CAS  Google Scholar 

  119. Mano-Otagiri A, Iwasaki-Sekino A, Nemoto T, et al. Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats. Regul Pept. 2010; 160:81–90.

    PubMed  CAS  Google Scholar 

  120. Davies JS, Kotokorpi P, Eccles SR, et al. Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. Mol Endocrinol. 2009;23:914–24.

    PubMed  CAS  Google Scholar 

  121. Gutierrez JA, Solenberg PJ, Perkins DR, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci U S A. 2008;105:6320–5.

    PubMed  CAS  Google Scholar 

  122. Gonzalez CR, Vazquez MJ, Lopez M, Dieguez C. Influence of chronic undernutrition and leptin on GOAT mRNA levels in rat stomach mucosa. J Mol Endocrinol. 2008;41:415–21.

    PubMed  CAS  Google Scholar 

  123. Thompson NM, Gill DA, Davies R, et al. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology. 2004;145:234–42.

    PubMed  CAS  Google Scholar 

  124. Rodriguez A, Gomez-Ambrosi J, Catalan V, et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond). 2009;33:541–52.

    CAS  Google Scholar 

  125. Liu J, Lin H, Cheng P, Hu X, Lu H. Effects of ghrelin on the proliferation and differentiation of 3T3-L1 preadipocytes. J Huazhong Univ Sci Technolog Med Sci. 2009;29:227–30.

    PubMed  CAS  Google Scholar 

  126. Dzamko NL, Steinberg GR. AMPK-dependent hormonal regulation of whole-body energy metabolism. Acta Physiol (Oxf). 2009;196:115–27.

    CAS  Google Scholar 

  127. Daval M, Diot-Dupuy F, Bazin R, et al. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem. 2005;280:25250–7.

    PubMed  CAS  Google Scholar 

  128. Orci L, Cook WS, Ravazzola M, et al. Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad Sci U S A. 2004;101:2058–63.

    PubMed  CAS  Google Scholar 

  129. Martinez-Agustin O, Hernandez-Morante J, Martinez-Plata E, de Sanchez MF, Garaulet M. Differences in AMPK expression between subcutaneous and visceral adipose tissue in morbid obesity. Regul Pept. 2010;163:31–6.

    PubMed  CAS  Google Scholar 

  130. Baran K, Preston E, Wilks D, Cooney GJ, Kraegen EW, Sainsbury A. Chronic central melanocortin-4 receptor antagonism and central neuropeptide-Y infusion in rats produce increased adiposity by divergent pathways. Diabetes. 2002;51:152–8.

    PubMed  CAS  Google Scholar 

  131. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest. 2006;116:1983–93.

    PubMed  CAS  Google Scholar 

  132. Andrews ZB, Erion DM, Beiler R, Choi CS, Shulman GI, Horvath TL. Uncoupling protein-2 decreases the lipogenic actions of ghrelin. Endocrinology. 2010;151:2078–86.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We are very grateful for the Rod Flower Summer Vacation Scholarship (MS), the sponsorship by Goldberg-Schachmann & Freda Becker Trusts (MS) and the Wellcome Trust Research Grant (BK, MK).

Author information

Authors and Affiliations

  1. Centre for Endocrinology, William Harvey Research Institute, Barts and The London, Queen Mary’s School of Medicine and Dentisty, Charterhouse Square, London, EC1M 6BQ, UK

    Miski Scerif M.B.B.S., B.Med.Sci., Blerina Kola M.D., Ph.D. & Márta Korbonits M.D., Ph.D.

Authors
  1. Miski Scerif M.B.B.S., B.Med.Sci.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Blerina Kola M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Márta Korbonits M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Márta Korbonits M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. , Department of Metabolism and Aging, The Scripps Research Institute Florida, Scripps Way 3B3 130, Jupiter, 33458, Florida, USA

    Roy G. Smith

  2. , Department of Medicine, University of Virginia, Ray C Hunt Drive 450, Charlottesville, 22908, Virginia, USA

    Michael O. Thorner

Rights and permissions

Reprints and Permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Scerif, M., Kola, B., Korbonits, M. (2012). Ghrelin Regulation of AMPK in the Hypothalamus and Peripheral Tissues. In: Smith, R., Thorner, M. (eds) Ghrelin in Health and Disease. Contemporary Endocrinology, vol 10. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-903-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-903-7_5

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-902-0

  • Online ISBN: 978-1-61779-903-7

  • eBook Packages: MedicineMedicine (R0)